The NIH Just Got a Haircut That Could Leave Biotech Bald
The NIH faces a historic 39.3% budget cut that would slash funding to levels not seen since 2003. A Senate hearing just examined what that means for the research pipeline that feeds every corner of the biotech industry.
Imagine building a house and then, right before you move in, someone rips out the foundation. That's roughly what a 39.3% cut to the National Institutes of Health would do to the American biotech industry.
On August 4, 2026, the Senate Finance Subcommittee on Health Care is scheduled to gather in a Dirksen hearing room to ask a question that should make every biotech investor, founder, and patient nervous: can biotechnology keep the U.S. health system resilient when the government is pulling billions from the research engine that powers it?
Back to 2003, But Without a Time Machine
The numbers are staggering. Under the FY2026 budget, NIH funding would drop to roughly $27.9 billion at the program level, down from about $47 billion the year prior. That's a massive haircut. To put it in perspective, the last time NIH operated at that funding level in nominal dollars was around 2003, when Congress had just finished doubling the agency's budget in a historic show of bipartisan support.
The previous largest recent cut? A decline of less than 1% in FY2024. Before that, you'd have to go back to the sequestration-era cuts of 2013 to find anything that even registered as painful. A near-40% reduction isn't just unprecedented; it's a different species of budget action entirely.
The hearing, titled "Building a Resilient Health Care Future with Biotechnology," features four witnesses: Alan D. Palkowitz of the Indiana Biosciences Research Institute, Kevin Outterson of CARB-X (a program fighting antibiotic-resistant bacteria), Vera P. Luther from Dartmouth's infectious disease division, and Michelle Rozo, vice chair of the National Security Commission on Emerging Biotechnology. The roster tells you everything about the scope of concern: this isn't just about lab budgets. It's about national security, pandemic preparedness, and whether we can still develop the drugs we need.
The Invisible Supply Chain Nobody Talks About
Most people think of drug development as something pharma companies do in sleek corporate labs. And they're not wrong, exactly. it takes to push a drug through clinical trials and across the FDA finish line.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Private industry funds more than 90% of the actual dollars
But where do those drugs come from in the first place?
Think of NIH funding like the farm system in baseball. Major league teams (pharma and biotech companies) get the glory, but their rosters depend on years of player development happening in the minors. NIH funds the basic biology: the target discovery, the mechanism studies, the early proof-of-concept experiments that tell you a drug idea is worth pursuing at all.
The data on this is striking. About 54% of basic science milestones in drug development are achieved by the public sector, compared to just 27% by private companies. One large-scale analysis found that 43% of NIH grants eventually led to research cited by private-sector patents. And a comprehensive review of drugs approved between 2010 and 2016 found that every single one of the 210 new drugs approved during that window had NIH-funded science somewhere in its lineage.
Every. Single. One.
The Domino Effect Is Already Visible
The damage from federal research cuts doesn't show up overnight. It works more like termites: invisible at first, catastrophic over time. But early signs are already emerging.
By mid-2025, roughly 2,300 NIH grants had been terminated, totaling nearly $2.45 billion. At least 160 clinical trials were among the casualties. A separate analysis estimated the economic ripple effect at about $6.3 billion in lost output from those terminated grants alone. Around 383 NIH-supported trials were disrupted between February and August 2025, affecting more than 74,000 participants.
Those aren't just numbers on a spreadsheet. Each terminated grant represents a lab that may close, a postdoc who may leave science, and a research question that may go unanswered for years.
Why This Hits Biotech Startups Hardest
Large pharma companies will weather this. They have deep pockets, diversified pipelines, and global operations. The real pain lands on early-stage biotech, the small companies that take academic discoveries and try to turn them into medicines.
These startups depend on a steady flow of "de-risked" science from universities: validated drug targets, animal model data, biomarker studies, and proof-of-concept packages that make investors comfortable enough to write checks. When NIH funding dries up, that supply chain breaks.
Econometric research puts a finer point on this. One study found that a sustained 10% reduction in disease-specific NIH funding leads to roughly 4.5% fewer related drugs entering early clinical trials, with effects that take up to 12 years to fully materialize. Scale that up to a 40% cut and the math gets ugly fast.
The talent pipeline is equally fragile. Graduate students and postdocs are the lifeblood of biotech hiring. Cut the grants that fund their positions, and you don't just lose a few lab assistants; you lose the next generation of company founders, research directors, and chief scientific officers. Industry leaders have warned that researchers may leave the field entirely or move abroad, creating a brain drain that could take decades to reverse.
The Three-to-Five-Year Horizon
Analysts across the industry point to the same uncomfortable timeline. The worst effects of these cuts won't be felt today or even next year. They'll surface in three to five years, when fewer early-stage companies advance through the pipeline, when therapeutic areas like oncology, infectious disease, and cardiovascular research see thinner portfolios, and when the U.S. starts losing its edge in biomedical innovation to countries that kept investing.
No private actor can fully replace what NIH does. Venture capitalists and pharma R&D budgets are built for calculated bets on science that's already been partially validated. The upstream, risky, slow, curiosity-driven research that NIH funds? That's too early and too uncertain for most commercial capital.
What Happens Next
It's worth noting that when the Trump administration proposed a similar-scale NIH cut for FY2026 in its original budget request, Congress ultimately rejected it and funded NIH at roughly $47.2 to $47.5 billion. The legislative process has a way of restoring what the executive branch tries to cut.
But the fact that we're having this hearing at all tells you the pressure isn't going away. Sen. Mike Crapo was listed among the key members for the session, and the subcommittee's framing (biotech resilience "in an era of intensifying competition and constrained federal funding") suggests this debate will define science policy for years.
The biotech industry was built on a handshake between public science and private capital. One side discovers the biology; the other side develops the drugs. If you break that deal, you don't just lose funding. You lose the future.
5 min read
Two CNS Pharma Companies Just Stitched Themselves Together. Here's Why.
Supernus and Indivior are merging into a $2.2 billion CNS and addiction powerhouse, combining ADHD drugs with the dominant opioid treatment franchise. It's specialty pharma's latest bet that brain disorders and addiction belong under one roof.
